Biotech Values

[DewDiligence]

>…the [Peg-Intron] label for second-line use must mean that there is sufficient trial data to support the hypothesis that non-responders to Pegasys are more likely to respond on a second try using Peg-Intron<

That’s my understanding.

> I'm thinking about this again in the context of the 'creative approach' IDIX has promised in dealing with non-responders in upcoming trials. One possibility I suggested previously was designing a trial (or trials) where non-responders to one type of peg-ifn are treated with NM283 plus the other type of peg-ifn, compared to a control arm w/o NM283, both w/ or w/o riba depending on the results of riba interaction studies. The other option is to use a combo of both peg-ifns, using around a half-dose of each<

This might work, but I’m hoping what they have in mind is somewhat more “creative.” We should know the answer within the next week.